Post-earnings recap
Reported
Mon, May 11, 2026
EPS actual
$2.83
EPS est.
$2.85
EPS surprise
-0.88%
1-day move
-2.70%
STERIS plc reported earnings that fell short of expectations, particularly in EPS. The stock reacted negatively, declining by 2.7%. Investors may be concerned about the company's performance and future outlook given the earnings miss and lack of revenue data.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.83 | $2.85 | -0.88% |
| Revenue | — | $1.6B | — |
No transcript is on record, and the analysis is based on numerical results only.
STERIS plc is a healthcare company that provides products and services for infection prevention and surgical procedures. With a market cap of $21 billion, it plays a crucial role in the healthcare equipment industry, particularly as demand for health-related services continues to grow.
Last quarter
In Q3 2026, STERIS reported an EPS of $2.53, matching analyst expectations. The stock saw a modest increase of nearly 1% the following day.
EPS beat streak
1Q
EPS beat rate
75%
Avg EPS surprise
+1.67%
Avg 1-day reaction
-0.41%
Analysts expect STERIS to report solid earnings, with a consensus EPS of $2.85. The market is closely watching how the company navigates ongoing challenges in the healthcare sector.
Bull case
If STERIS exceeds EPS expectations, it could signal strong demand for its products and services, potentially boosting investor confidence.
Bear case
Conversely, if the company misses EPS estimates, it may raise concerns about its growth prospects and market position.
Key metrics to watch
EPS
$2.85Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$1.6BRevenue figures provide insight into the company's sales performance and market demand.
The print will turn on these.
Q1
Will STERIS achieve an EPS of $2.85 or higher?
This figure is critical as it sets the tone for investor confidence and reflects the company's profitability.
Q2
What insights will management provide regarding revenue growth?
Understanding revenue trends can indicate how well STERIS is performing in the competitive healthcare market.
—
Est. EPS
$0.97
Est. Rev
$693M
Impl. Move
±7.6%
Why consensus could be wrong
The consensus may be underestimating the impact of recent healthcare trends on STERIS's revenue growth potential.
Supporting evidence
The company's strong historical EPS beat rate of 88% suggests it often exceeds expectations.
Options pricing indicates a significant expected move, which may reflect uncertainty not captured in consensus estimates.
Key risk
If management provides strong guidance on revenue growth, it could challenge the current consensus outlook.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal as it reflects STERIS's ability to navigate market challenges and meet investor expectations.
Bull confirmed if
An EPS of $2.90 or above would confirm strong operational performance.
Bear confirmed if
An EPS below $2.81 could indicate underlying issues affecting profitability.
What the market is pricing for the move.
Implied Move
±5.6%
Historical Avg
±1.0%
The options market is pricing in a significant move following the earnings report, suggesting heightened volatility expectations.
Options are pricing ±6.0% while STE has averaged ±1.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
24.0%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich setup in Health Care
Fade rate: 6 of 12 (50%)
This setup has occurred 30 times across Health Care in the last 2 years. 6 of 12 faded and 6 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 4.5%, with a raw directional average of -0.4% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
100.75%
of float
Insider
0.31%
of float
Holders
1,218
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
8,820,889 sh · $1.8B
9.05%
-2.3%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If STERIS beats expectations, history suggests the stock could see a modest increase, confirming positive market sentiment.
In line / cautious
If results are in line with expectations, the stock may remain stable, but cautious commentary could lead to volatility.
Miss
A miss on EPS could lead to a decline, with history suggesting an average drop of around 1% following such outcomes.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
12
5 buys·7 sells
Members
4
House only
Est. Notional
$125,012.00–$450,000.00
disclosed dollar ranges
Most Active Members
6 trades
The lines on the call that would change the story.
Vanguard Capital Management LLC
6,406,906 sh · $1.3B
6.57%
0.6%
State Street Corporation
5,072,818 sh · $1.1B
5.20%
1.6%
Vanguard Portfolio Management LLC
5,001,950 sh · $1.0B
5.13%
1.1%
Morgan Stanley
3,950,067 sh · $828.3M
4.05%
-10.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Mixed
4 trades
Net buying
1 trade
Net selling
1 trade
Net selling
Recent Transactions
Traded Sep 15, 2026 · disclosed Sep 25, 2026
$15,001.00–$50,000.00
Traded Aug 25, 2026 · disclosed Sep 9, 2026
$100,001.00–$250,000.00
Traded Jul 31, 2026 · disclosed Aug 3, 2026
$1,001.00–$15,000.00
Traded Jul 29, 2026 · disclosed Aug 3, 2026
$1,001.00–$15,000.00
Traded Jul 27, 2026 · disclosed Aug 3, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.